Please upgrade your browser.
Scientists think they're close to understanding all of the abnormal genes which cause kidney cancer.
Good luck to Mr Cameron in shaking up the NHS. Putting back a caring culture on our wards would cost nothing but would transform peoples experience of hospitals.
Research findings, 'A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy,' are discussed in a new report.
Applications will be submitted by the firm to the European Medicines Agency and US Food and Drug Administration (FDA) later this year...
Kidney cancer affects 8,500 people every year in Italy, but it is not a very well known disease. Patients need all information we have on innovative therapies and recent findings. Only in the last few months, new molecules, targeted bullets, are available to Italians. These agents are able to prolong patients survival.
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
Sunitinib treatment is associated with an early increase of Circulating endothelial cells (CEC) in responding patients, suggesting superior endothelial cell damage in these patients as a putative predictive biomarker.
The full analysis appears online today in the Journal of the National Cancer Institute.
An aging population, improved screening, and more effective therapies have resulted in a steadily increasing number of patients and cancer survivors.
Surveyed oncologists who identified Sutent as having the best overall clinical profile assigned low satisfaction scores to the drugs out-of-pocket costs and its overall cost, said Decision Resources Analyst Ramya Kollipara, Ph.D. Although it is covered by many insurance companies, Sutent is not available generically and appears on the second tier of many MCO formularies."
|NeonCRM by Neon One|